Cultured Human Cell Monolayers Cryopreserved In Situ

原位冷冻保存培养的人类单层细胞

• 批准号: 6933461
• 负责人: John M BAUST
• 金额: $ 13.95万
• 依托单位: CELL PRESERVATION SERVICES, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-12 至 2006-09-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6933461
• 关键词: cell adhesion; cryopreservation; growth media; human genetic material tag; solutions; technology /technique development; tissue /cell culture

DESCRIPTION (provided by applicant): Cell Preservation Services Inc (CPSI) develops new approached for low temperature storage of cellular system. CPSI's strategy is designed around the molecular events underlying cell death cascades that are launched due to extensive cell stress. Once known, methods are developed which modulate these cell death processes and improve cell survival. CPSI's scientist?s recent involvement in developing a new cryopreservation media (CryoStor), coupled with current associations with preservation media companies (BioLife Solutions - CryoStor) and other biotech companies who distribute primary human liver and skin cells, has precipitated CPSI's interest in further exploring in situ cryopreservation methodologies and devices to bulk freeze (process) multiwell dishes containing human cells. The proposed investigations build upon approaches and studies that current CPSI scientists have been working on since the late-1990?s. The intent of this proposal is to accomplish the following: SA1 - Identify the best carrier medium to use as the cryopreservation solution for in situ cryopreservation; SA2 - Test a cocktail of cryoprotective agents to determine those that confer the maximum cryoprotection; SA3 - Test different cell adhesion and culture matrices for their abilities to maximize the adhesion of human cells subsequent to thawing; SA4 - Test proprietary cell culture plates to identify suitable candidates for the process. SA5- Identify cooling rates that maximize cell survival; SA6 ? Compare cell viability and function in cells preserved in situ to those preserved using conventional suspended technology. Phase II will be dedicated to scaling up the process for high throughput screening (i.e. 384 well plates, one year storage time at -80C). CPSI plans to license the developed technology to both small biotechnology companies and large pharmaceutical industries in Phase III.

描述（由申请人提供）：Cell Preservation Services Inc（CPSI）开发了细胞系统低温储存的新方法。 CPSI的策略是围绕细胞死亡级联的分子事件而设计的，这些细胞死亡级联是由于广泛的细胞应激而启动的。 一旦已知，就开发了调节这些细胞死亡过程并改善细胞存活的方法。CPSI的科学家？最近，CPSI参与开发了一种新的冷冻保存介质（Cryopreservation media），再加上目前与保存介质公司（BioLife Solutions -Cryopreservation）和其他生物技术公司的合作，这些公司分销原代人类肝脏和皮肤细胞，这促使CPSI对进一步探索原位冷冻保存方法和设备以批量冷冻（处理）含有人类细胞的多孔培养皿产生了兴趣。 拟议的调查建立在目前CPSI科学家自1990年底以来一直在研究的方法和研究的基础上？S. 本建议的目的是完成以下工作：SA 1-确定用作原位冷冻保存的冷冻保存溶液的最佳载体培养基; SA 2-测试冷冻保护剂的混合物，以确定提供最大冷冻保护的冷冻保护剂; SA 3-测试不同细胞粘附和培养基质在解冻后使人细胞粘附最大化的能力; SA 4-检测专有细胞培养板，以确定工艺的合适候选物。SA 5-确定最大化细胞存活的冷却速率; SA 6？比较原位保存的细胞与使用传统悬浮技术保存的细胞的细胞活力和功能。第II阶段将致力于扩大高通量筛选工艺（即384孔板，在-80 ℃下储存一年）。CPSI计划在第三阶段将开发的技术授权给小型生物技术公司和大型制药行业。